Ozonated Water in Treatment of Denture Stomatitis
Effect of Ozone Water in Treatment of Denture Inflammation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 12622
- National Research Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Completely edentulous male patients wearing heat cured acrylic resin removable prosthesis.
- Patients having denture associated oral stomatitis.
- Healthy patients free of any systemic diseases.
Exclusion Criteria:
- Smoker patients.
- Patients suffering from any auto immune or systemic diseases, Temporo-mandibular joint disorder ( TMJ disorders and parafunctional oral habits.
- Patients with a history of radiotherapy or chemotherapy.
- Patients having oral lesions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group I patients treated with ozonated water
The patients were used ozonated water as mouth wash for treatment of denture associated oral stomatitis.
|
ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min.
in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
|
|
Active Comparator: Group II patients treated with chlorhexidine mouthwash
The patients were used chlorhexidine mouth wash for treatment of denture associated oral stomatitis
|
Commercial available chlorhexidine mouthwash in the market was used.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Candida albicans colonies
Time Frame: day one, 7th day, 14th day and 30th day
|
The number of Candida albicans forming units (CFU) was used to assess the effect of two types of treatments.
|
day one, 7th day, 14th day and 30th day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
-Evaluation of inflammation and pain grade
Time Frame: day 1, and 30th day
|
- Evaluation of inflammation and pain grade by questionnaire
|
day 1, and 30th day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Asmaa N, Elboraey, Ass,Pro, National Research Centre, Egypt
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4447082022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.